The utility of digital rectal examination (DRE) as a screening test for early detection of prostate cancer has not been established.
Therefore, we evaluated the usefulness of DRE as a stand-alone screening test and in conjunction with measured serum prostate-specific antigen (PSA) levels of 0-3.9 ng/mL and transrectal ultrasonography (TRUS).
Our study population consisted of 10 523 men aged 54-76 years who were randomly assigned to the screening arm of the Rotterdam, The Netherlands, section of the European Randomized Study of Screening for Prostate Cancer.
The underlying prevalence of detectable prostate cancer was estimated by logistic regression analysis and used for calculating the sensitivity of DRE as a test.
Pathologic characteristics of 105 radical prostatectomy specimens were used to determine the aggressiveness of the tumors diagnosed (and missed) by DRE.
The overall detection rate for prostate cancer in this population when serum PSA measurement, DRE, and TRUS were used was 4.5%, and the detection rate with DRE alone was 2.5%. The positive predictive value of DRE ranged from 4% to 11% in men with PSA levels of 0-2.9 ng/mL and from 33% to 83% in men with PSA levels of 3.0-9.9 ng/mL or more.
Most tumors detected by DRE in men with PSA levels of less than 4.0 ng/mL were small (mean volumes=0.24-0.83 mL), and most were well differentiated (Gleason scores of 6 or less). (...)
Mots-clés Pascal : Tumeur maligne, Prostate, Dépistage, Toucher rectal, Antigène spécifique prostate, Marqueur tumoral, Diagnostic, Pays Bas, Europe, Homme, Appareil génital mâle pathologie, Appareil urinaire pathologie, Prostate pathologie
Mots-clés Pascal anglais : Malignant tumor, Prostate, Medical screening, Rectal touch, Prostate specific antigen, Tumoral marker, Diagnosis, Netherlands, Europe, Human, Male genital diseases, Urinary system disease, Prostate disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0023643
Code Inist : 002B14D02. Création : 31/05/1999.